P2X3 inhibitor shows 75 percent reduction in chronic cough frequency Date: November 25, 2014 Source: Burns McClellan Summary: Results from a Phase 2 clinical trial have been published ...

Afferent Pharmaceuticals is announcing online publication in The Lancet of results from a Phase 2 clinical trial demonstrating that Afferent's drug candidate -- AF-219 -- reduced daytime cough ...

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores assessing cough severity and cough-related quality of life at day 28 ...

Smith J, Morice AH, Birring SS, et al. Improvements in cough frequency over 24 hours with BLU-5937, a selective P2X3 antagonist, in patient subgroups defined by baseline awake cough frequencies.

Laval, Quebec-based Bellus aims to treat the coughing condition with camlipixant, a small molecule that blocks P2X3, a receptor associated with the cough mechanism.

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended ...

MILAN -- Twice-daily doses of the oral P2X3 receptor antagonist gefapixant may improve refractory or unexplained chronic cough, but at the cost of adverse events, a meta-analysis and systematic ...

Recent findings suggest that post-COVID chronic cough may be driven by neurologic factors, not just respiratory issues.

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with ...

The acquisition provides GSK access to Camlipixant, a P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. The decision ...